Work

Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2519

Authors: Kathleen N. Moore, Johanna C. Bendell, Anthony J. Olszanski, Madhuri Desai, Mendel Jansen, Richard David Scheyer, Giorgio Senaldi, Patricia LoRusso

Institutions: University of Oklahoma Health Sciences Center, Tennessee Oncology, Fox Chase Cancer Center, Daiichi Sankyo (United Kingdom), Wayne State University, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597088542

Cites:

Cited by: 1

Related to: 10